Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

J&J Plans for the Future by Trimming Pension Benefits for New Hires

September 15, 2014
Life sciences
In its latest step to cut costs, Johnson & Johnson JNJ +0.03% will reduce pension benefits that are offered to employees who are hired – or rehired – after Jan. 1, according to an internal memo.
 
The changes, which do not apply to existing employees or retirees, were not detailed, but reflect the way the “benefit landscape has continued to evolve in recent years,” as well as “emerging trends” in employee career patterns and practices at competitors, writes Peter Fasolo, the J&J JJSF -1.22% worldwide vice president for human resources. A J&J spokeswoman confirms the memo was sent to employees.
 
“The changes will more closely align with benefits offered by our competitors and maintain a retirement program that’s above average among our peer companies,” he writes. “… More importantly, it will continue to support our efforts to attract and retain talent to drive innovation and growth across our family of companies, helping us manage for the long term.”
 
The move comes even as J&J, which sells a wide array of prescription drugs, medical devices and over-the-counter health products, continues to improve its financial performance. Sales in the second quarter this year, for instance, rose 9%, while earnings climbed more than 12%.
 
The healthcare giant has been attempting something of a turnaround, despite sluggish device sales and efforts to revive its over-the-counter business, which was plagued in recent years with embarrassing manufacturing gaffes that led to numerous product recalls.
 
The pharmaceuticals business, however, has been a stand out. In the second quarter, prescription drug revenue jumped 21%, thanks to sales of treatments for prostate cancer and psoriasis, among other. Over the past year, J&J stock has risen nearly 20%.
 
Like many other companies, though, J&J continues to cut costs. Earlier this year, the DePuy Synthes medical device unit eliminated all travel – except for sales reps – for the rest of this year in hopes of lowering those costs by 25% and meeting 2014 financial goals.
 
By Ed Silverman
 
Source: Pharmalot

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach